Success Stories: A Postdoctoral Fellow in Molecular Medicine Secures EB1A Approval in Just 8 Days via the Premium Processing

Client’s Testimonial:

“I had an excellent experience working with Chen Immigration Law associates on my EB1A green card application. Their team was highly knowledgeable, responsive, and thorough throughout the entire process. The portal is full of useful information and easy to use. They helped present my case in the strongest possible way, guiding me step by step with clear communication and expert advice. Thanks to their dedication and strategic approach, my petition was approved smoothly. I highly recommend Chen Immigration Law associates to anyone pursuing an EB1A or other immigration path.”

On May 8^th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Fellow in the Field of Molecular Medicine (Approval Notice).

General Field: Molecular Medicine

Position at the Time of Case Filing: Postdoctoral Fellow

State of Residence at the Time of Filing: New York

Approval Notice Date: May 8^th, 2025

Processing Time: 8 days (Premium Processing Requested)

Case Summary:

A distinguished postdoctoral fellow, working in the field of molecular medicine, recently secured approval for his I-140 petition under the EB-1A (Alien of Extraordinary Ability) category. Filed with the direct premium processing, the petition was approved in just 8 days, highlighting the exceptional strength of his academic and research credentials.

Recognized as a thought leader in nanomedicine and immunology

Our client’s research spans targeted cancer therapy, RNA-based therapeutics, and chronic inflammatory disease treatment, placing him among the top contributors in these rapidly evolving fields. His work has resulted in major scientific breakthroughs, particularly in delivering RNA and CRISPR-based therapeutics using lipid nanoparticle platforms.

After he reached our law firm, our team developed a strategy that demonstrated his sustained acclaim and documented record of original contributions, showing how his innovations have been widely cited, implemented, and advanced by the global scientific community.

Achievements that position him at the top of his field

In support of the EB1A petition, we documented the following case highlights:

● 20 peer-reviewed journal articles (7 first-authored), 2 scientific abstracts, and 2 book chapters, with at least one first-authored in each category, many of which appeared in top-tier journals, showcasing his exceptional publication record

● 4,265 total citations, demonstrating the global impact and sustained relevance of his research

● At least 12 papers ranked among the most highly cited in Molecular Biology & Genetics for their year of publication

● h-index of 17, placing him in the top 3% of authors in medicine

● Completed 30+ peer reviews for journals such as Science Immunology, Trends in Biotechnology, and Journal of Controlled Release

● Served as guest editor for special issues in Nanotechnology and the International Journal of Molecular Sciences

● Research supported by prestigious institutions including the NIH, European Research Council, Israel Science Foundation, and Israel Cancer Research Fund

A proposed endeavor aligned with U.S. biomedical priorities

Our client plans to continue innovating in molecular therapeutics, particularly through the development of RNA-delivery platforms and immunomodulatory therapies. His goal is to further optimize gene and protein delivery technologies to treat cancer and inflammatory diseases, contributing to national objectives in precision medicine and pharmaceutical innovation.

Expert testimonials confirm national importance

The petition included four recommendation letters, with three written by independent experts unaffiliated with the client. These letters affirmed the originality of his contributions and the importance of his research to national biomedical goals. One expert stated:

“[Client’s] research in RNA-based molecular therapy, which uses LNPs to target immune cells, is improving treatment precision. He developed a way to selectively deliver RNA therapies directly to disease-causing immune cells, improving outcomes in colitis and other inflammatory conditions. Physicians and researchers in the U.S. are actively using these insights to develop patient-specific therapies that reduce reliance on broad-spectrum immunosuppressants. Overall, [client] is shaping precision medicine, facilitating the development of more effective, personalized, and safer treatments, thus making him an indispensable asset to the United States.”

EB1A approved in only 8 days

We are proud to announce that the client’s EB1A petition was approved just 8 days after submission, thanks to the strength of the petition and the use of the premium processing. We congratulate him on this well-earned success and are honored to support his continued contributions to the future of biomedical research in the United States.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.